Nymox Pharmaceutical Corporation (NYMXF)

Market Cap	5.42M -17.2%
Revenue (ttm)	n/a
Net Income	-4.49M
EPS	-0.05
Shares Out	102.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,702
Average Volume	15,885
Open	0.0505
Previous Close	0.0507
Day's Range	0.0505 - 0.0507
52-Week Range	0.0322 - 0.1495
Beta	14.63
RSI	51.88
Earnings Date	Mar 13, 2026

About Nymox Pharmaceutical

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer’s disea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1989
• Employees: 16
• Stock Exchange: OTCMKTS
• Ticker Symbol: NYMXF